Brought to you by 
TiGenix NV closes €16mm Series B round
03 Feb 2006
Executive Summary
TiGenix NV, a developer of osteoarthritis treatments, brought in €16mm ($19mm) through its Series B financing round led by ING Corporate Finance. Other returning shareholders Capricorn Venture Partners, Auriga Partners, and Fagus (managed by Fortis Private Equity) were joined by new investors HSS Ventures, ITX Corp., Banque Générale de Luxembourg, Baekeland Fonds 2, SRIW, and Partners@Venture.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TiGenix NV closes €16mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice